Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary or secondary myelofibrosis; 46 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Sørensen, Anders Lindholm, Mikkelsen, Stine Ulrik, Knudsen, Trine Alma, Bjørn, Mads Emil, Andersen, Christen Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Patel, Dustin Andersen, Gjerdrum, Lise Mette Rahbek, El Fassi, Daniel, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits-Andersen, Hans Torben, Nielsen, Claus Henrik, Ellervik, Christina, Pallisgaard, Niels, Thomassen, Mads, Kjær, Lasse, Skov, Vibe, Hasselbalch, Hans Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556624/
https://www.ncbi.nlm.nih.gov/pubmed/33054051
http://dx.doi.org/10.3324/haematol.2019.235648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556624/
https://www.ncbi.nlm.nih.gov/pubmed/33054051
http://dx.doi.org/10.3324/haematol.2019.235648

Ejemplares similares